Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed this Current Report on February 21, 2024, reporting events effective February 16, 2024. The filing concerns executive compensation changes required under the company’s January 12, 2024 securities purchase agreement with Dragasac Limited. Celularity is a Delaware life sciences company whose Class A common stock and warrants trade on Nasdaq under CELU and CELUW.
Key Financial and Compensation Matters
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics.
- Annual 2024 base salaries for members of the executive leadership team were reduced by 15%, effective February 16, 2024. The reductions are temporary, with prior salary rates scheduled to resume on January 1, 2025.
- Robert J. Hariri voluntarily reduced his 2024 annual base salary rate by 85% to $180,000.
- Other disclosed 2024 annual base salaries are: David Beers, $361,250; Stephen Brigido, D.P.M., $361,250; K. Harold Fletcher, Esq., $323,000; John Haines, $425,000; and Adrian Kilcoyne, M.D., $403,750.
- Dr. Hariri’s unpaid 2023 base salary of $1,087,611.83 will not be paid unless Celularity raises at least $21.0 million of additional cash through qualifying equity offerings at specified valuation or pricing levels.
- If those performance conditions are satisfied, a bonus program provides for payment to Dr. Hariri equal to 125% of the unpaid 2023 base salary, subject to the agreement terms and Internal Revenue Code Section 409A requirements.
- Stock options were granted to executive officers under the 2021 Equity Incentive Plan. The options have an exercise price equal to Celularity’s February 16, 2024 closing stock price, vest quarterly over one year, and expire after 10 years.
Material Changes Versus the Prior Comparable Period
- The filing implements temporary 2024 salary reductions that were not in effect at the prior salary rates.
- Dr. Hariri’s compensation structure changed from suspended 2023 salary payments to a contingent bonus arrangement tied to future equity fundraising.
- New executive stock option grants were approved, including 2,937,788 options for Dr. Hariri, 183,612 each for Mr. Beers and Dr. Brigido, 164,171 for Mr. Fletcher, 216,014 for Mr. Haines, and 205,213 for Dr. Kilcoyne.
Guidance, Outlook, Risks, and Unusual Items
- No operating or financial guidance was provided.
- The contingent payment to Dr. Hariri depends on Celularity raising at least $21.0 million in qualifying equity financing and meeting specified valuation or pricing requirements.
- The temporary salary reductions and equity awards were conditions contemplated by the Dragasac securities purchase agreement.
- The option grants may increase share dilution; the filing does not state the February 16 closing share price or the aggregate potential dilution.
Investor Verification Items
- Review the Dragasac securities purchase agreement and related amendments to confirm the financing conditions and pricing requirements.
- Verify whether the required equity financing was completed and whether Dr. Hariri’s contingent bonus became payable.
- Confirm the February 16, 2024 closing stock price used as the option exercise price.
- Assess the potential dilution from the disclosed option grants and any other grants to the executive leadership team.
- Review Exhibits 10.1 through 10.6 for the complete employment agreement amendments and compensation terms.